TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27600181

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 539

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 539
Study: 24666560

Group type: EXPERIMENTAL
Intervention: Bilateral global pelvic manipulation (GPM) technique (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham (placebo) intervention (control group)
Number of subjects: 40
Study: 21474911

Group type: EXPERIMENTAL
Intervention: Rehabilitation plus controlled breathing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 40
Study: 20515219

Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretation
Number of subjects: 100
Study: 18686770

Group type: EXPERIMENTAL
Intervention: Fiber posts cemented with resin cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titanium posts cemented with resin cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titanium posts cemented with glass ionomer
Number of subjects: 40
Study: 15816573

Group type: COMPARATOR
Intervention: Saline 2 mL (Group S)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1) (Group K)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg kg(‐1) (Group E)
Number of subjects: 75
Study: 12460587

Group type: EXPERIMENTAL
Intervention: Androstadienone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Androstenol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Muscone
Number of subjects: 37
Study: 10619585

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium, twice daily for 16 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (twice daily for 16 weeks)
Number of subjects: 32
Study: 8739589

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group of older untreated affected siblings
Number of subjects: 10
Study: 1921241

Group type: EXPERIMENTAL
Intervention: Intravenous zinc supplementation for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7086609

Group type: EXPERIMENTAL
Intervention: Forced convection incubator (air velocity 15 to 25 cm/second)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Still-air incubator (air velocity 0 to 2 cm/second)
Number of subjects: 0
Study: 31023200

Group type: EXPERIMENTAL
Intervention: One suture-button device (OSB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Two suture-button devices (TSB)
Number of subjects: 80
Study: 28721578

Group type: EXPERIMENTAL
Intervention: Chair massage program
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Relaxing music sessions
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 26050650

Group type: EXPERIMENTAL
Intervention: Vincristine-steroid pulses during maintenance
Number of subjects: 1223

Group type: COMPARATOR
Intervention: IKZF1 deletion (IKZF1(del))
Number of subjects: 1223

Group type: COMPARATOR
Intervention: IKZF1 deletion in high hyperdiploid ALL
Number of subjects: 1223

Group type: COMPARATOR
Intervention: IKZF1 deletion in 'B-other' ALL
Number of subjects: 1223
Study: 23520132

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Mean DCCT/EDIC HbA1c over time
Number of subjects: 1017
Study: 21610711

Group type: EXPERIMENTAL
Intervention: Oral temozolomide (200 mg m(‐2) per day; days 1‐5)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous dacarbazine (800 mg m(‐2); day 1)
Number of subjects: 150
Study: 19628194

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 16112498

Group type: EXPERIMENTAL
Intervention: QR-333
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12456450

Group type: EXPERIMENTAL
Intervention: Ciaglia Blue Rhino (CBR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Griggs' guidewire dilating forceps (GWDF)
Number of subjects: 60
Study: 10333035

Group type: EXPERIMENTAL
Intervention: circuit treated with surface modifying additive
Number of subjects: 34

Group type: COMPARATOR
Intervention: standard circuit (control group)
Number of subjects: 34
Study: 8727142

Group type: EXPERIMENTAL
Intervention: 67 degrees C radiofrequency lesion adjacent to the dorsal root ganglion
Number of subjects: 20

Group type: COMPARATOR
Intervention: No actual radiofrequency lesion made
Number of subjects: 20
Study: 1837121

Group type: EXPERIMENTAL
Intervention: Horse ALG 15 mg/kg just before transplant surgery; ALG 12 mg/kg on the first day after transplant followed by 4 doses of 10 mg/kg on alternate days; CyA p.o 8 mg/kg/d; prednisone 0.25 mg/kg/d
Number of subjects: 101

Group type: COMPARATOR
Intervention: OKT3 5 mg just before transplant followed by 4 doses of 5 mg/d.; CyA and prednisone were administered using the same schedule as group A
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Horse ALG
Number of subjects: 101

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 101
Study: 6819969

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) with low-dose prednisone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional immunosuppression (ALG, prednisone, and azathioprine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional immunosuppression
Number of subjects: 100
Study: 31549903

Group type: EXPERIMENTAL
Intervention: Text messaging follow-up (received messages at 24 hours, 1 week, and 2 weeks after discharge)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Text messaging follow-up
Number of subjects: 802

Group type: COMPARATOR
Intervention: Usual care (typically no dedicated communication)
Number of subjects: 802
Study: 31526670

Group type: EXPERIMENTAL
Intervention: VMATAuto (automatically generated volumetric modulated arc therapy plans)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: VMATAuto
Number of subjects: 40

Group type: COMPARATOR
Intervention: VMATAuto, VMATClinical, VMATIdeal
Number of subjects: 40
Study: 29082831

Group type: EXPERIMENTAL
Intervention: Mindfulness program based on brief integrated mindfulness practices (M-PBI) for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mindfulness program (M-PBI)
Number of subjects: 40
Study: 26329950

Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Abdominal Hysterectomy (Group B)
Number of subjects: 60
Study: 25608546

Group type: EXPERIMENTAL
Intervention: Emotional intelligence program (4 weeks, 8 sessions, 20 hours)
Number of subjects: 36
Study: 22267374

Group type: EXPERIMENTAL
Intervention: Clofibrate and intensive phototherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intensive phototherapy
Number of subjects: 52
Study: 19898645

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of 0.03 mmol BQ123 (selective endothelin A-receptor blocker)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 15
Study: 17763271

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of (1/2) normal saline (NS) at a rate of 1000 mL/h for two hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous infusion of (1/2) NS at 10 mL/h for two hours
Number of subjects: 44
Study: 14648013

Group type: EXPERIMENTAL
Intervention: Auditory feedback
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combined visual-auditory feedback
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (auditory feedback)
Number of subjects: 54
Study: 11943970

Group type: EXPERIMENTAL
Intervention: Home-based intervention with weekly visits until 6 months postpartum and biweekly visits from 6 to 18 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group with brief monthly tracking visits
Number of subjects: 131
Study: 9743270

Group type: EXPERIMENTAL
Intervention: Modafinil (exact dosage and duration not specified)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Normal controls (not specified if treated or untreated)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Patients with narcolepsy
Number of subjects: 530
Study: 7707852

Group type: EXPERIMENTAL
Intervention: Ringer's solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified Carolina rinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Autologous blood
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simultaneous portal and arterial reperfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sequential portal and arterial reperfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elderly donors
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prolonged cold storage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Marked steatosis
Number of subjects: 60
Study: 2696434

Group type: COMPARATOR
Intervention: somatropin
Number of subjects: 13
Study: 608538

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum, 5 mg/m2 i.v.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 18
Study: 30986119

Group type: EXPERIMENTAL
Intervention: 0.05% Cyclosporin A topical nanoemulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cyclosporin A emulsion
Number of subjects: 0
Study: 29961848

Group type: EXPERIMENTAL
Intervention: Community scheduled malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHWs) plus IPTp-SP
Number of subjects: 0

Group type: COMPARATOR
Intervention: IPTp-SP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing number of IPTp-SP doses
Number of subjects: 0
Study: 30187739

Group type: EXPERIMENTAL
Intervention: KNO3 1% + ground brick + Bacillus sp., CKD061
Number of subjects: 0

Group type: COMPARATOR
Intervention: Without treatment (A0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ground brick matri-conditioning + Bacillus sp., CKD061 (A2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ground burned-rice husk matri-conditioning + Bacillus sp., CKD061 (A3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ground brick matri-conditioning + Bacillus sp., CKD061 + KNO3 1% (A4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ground burned-rice husk matri-conditioning + Bacillus sp., CKD061 + KNO3 1% (A5)
Number of subjects: 0
Study: 26234623

Group type: EXPERIMENTAL
Intervention: Zirconia frameworks veneered with pressed ceramic (IPS e.max ZirPress)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Layered veneering ceramic (IPS e.max Ceram)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both test and control groups
Number of subjects: 40
Study: 22692118

Group type: EXPERIMENTAL
Intervention: Combined sled towing and sprint training (SLED)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional sprint training (TRAD)
Number of subjects: 20
Study: 21557241

Group type: EXPERIMENTAL
Intervention: Type I thyroplasty
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Graft implantation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Injection laryngoplasty
Number of subjects: 28
Study: 19192977

Group type: EXPERIMENTAL
Intervention: Personal and Social Performance scale (PSP)
Number of subjects: 1964
Study: 15823293

Group type: EXPERIMENTAL
Intervention: Diacylglycerol oil (DAG) ingestion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Triacylglycerol oil (TAG) ingestion
Number of subjects: 18
Study: 12075248

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 8000
Study: 9482167

Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7614957

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Benzylpenicillin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 334
Study: 2650700

Group type: EXPERIMENTAL
Intervention: Low doses of n-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very high doses of n-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of n-3 fatty acids
Number of subjects: 0
Study: 69143

Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous aminoacids
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous fat
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 4
Study: 29843074

Group type: EXPERIMENTAL
Intervention: Couple-based intervention delivered to women and men jointly
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Gender-focused intervention delivered to women and men separately
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard HIV testing and counseling offered to women only (comparison arm)
Number of subjects: 299
Study: 27479847

Group type: EXPERIMENTAL
Intervention: Postconcussion symptom scale
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Abrupt increase in mental activity (returning to school and extracurricular activities)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Initial symptom severity in emergency department
Number of subjects: 63
Study: 24102238

Group type: EXPERIMENTAL
Intervention: Instrumented measure for passive ankle dorsiflexion under anaesthesia
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Instrumented measure for passive ankle dorsiflexion when conscious
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Instrumented measure for passive ankle dorsiflexion (anaesthetized)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Instrumented measure for passive ankle dorsiflexion (conscious)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Previously reported dorsiflexion measures in conscious children with CP
Number of subjects: 34
Study: 22424013

Group type: EXPERIMENTAL
Intervention: Left ventricular contractile reserve (LVCR) present
Number of subjects: 221

Group type: COMPARATOR
Intervention: No left ventricular contractile reserve (LVCR)
Number of subjects: 221
Study: 21250570

Group type: EXPERIMENTAL
Intervention: DPSS laser (500 mW/cm2) for 40 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DPSS laser (500 mW/cm2) for 10 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: QTH light (800 mW/cm2) for 40 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DPSS laser (500 mW/cm2) for 20 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 18392675

Group type: EXPERIMENTAL
Intervention: Growth hormone co-treatment (4 mg daily subcutaneous injection from day 21 of preceding cycle until hCG)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Growth hormone co-treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (same treatment protocol without growth hormone)
Number of subjects: 61
Study: 16355609

Group type: EXPERIMENTAL
Intervention: Shenzhe Zhuyun mixture (SZM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cisapride (Control)
Number of subjects: 64
Study: 12225396

Group type: EXPERIMENTAL
Intervention: TAD (daunorubicin, cytosine arabinoside (ara-C), and thioguanine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TAA (aclarubicin substituted for daunorubicin)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both TAD and TAA
Number of subjects: 90
Study: 9720330

Group type: EXPERIMENTAL
Intervention: i.v. fentanyl 0.1 mg followed by bolus injection of cold propofol premixed with lidocaine (final concentration of lidocaine was 0.2%) in a forearm vein without carrier i.v. fluid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Induction dose of propofol via a vein on the dorsum of the hand at a slow injection speed with carrier i.v. fluid
Number of subjects: 60
Study: 8587456

Group type: COMPARATOR
Intervention: Nitroglycerin (1 microgram/kg/min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diltiazem (3 micrograms/kg/min)
Number of subjects: 32
Study: 2527891

Group type: EXPERIMENTAL
Intervention: Continuation treatment with nortriptyline or phenelzine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 51958

Group type: EXPERIMENTAL
Intervention: Recombinant WRL 105 vaccine (10^7.0 E.I.D.50 administered as nose drops)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recombinant WRL 105 vaccine
Number of subjects: 25
Study: 31036546

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM) system
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 101
Study: 28772048

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 4 × 4 min at 85-90% peak heart rate, 3 days/week for 4 weeks, n=9
Number of subjects: 15

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic continuous training (MI-ACT) - 30 min at 70% peak heart rate, 3 days/week for 4 weeks, n=6
Number of subjects: 15
Study: 25499666

Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35-mg capsules under fasting conditions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35-mg capsules under fed conditions
Number of subjects: 40

Group type: COMPARATOR
Intervention: diclofenac potassium IR 50-mg tablets under fasting conditions
Number of subjects: 40

Group type: COMPARATOR
Intervention: diclofenac potassium IR 50-mg tablets under fed conditions
Number of subjects: 40
Study: 23781136

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic therapy (threshold of 0.25 ng/ml)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine treatment (standard practice)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group
Number of subjects: 61
Study: 21543343

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg/d)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Resistant Starch (30 g/d)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Exploratory endpoint - Resistant Starch (30 g/d)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Laboratory measures of proliferation
Number of subjects: 206
Study: 19221977

Group type: EXPERIMENTAL
Intervention: 1,000 mg pinitol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pinitol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 15
Study: 17179098

Group type: EXPERIMENTAL
Intervention: Dofequidar + CAF (Cyclophosphamide, Doxorubicin, and Fluorouracil)
Number of subjects: 221

Group type: COMPARATOR
Intervention: CAF (Cyclophosphamide, Doxorubicin, and Fluorouracil)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Dofequidar + CAF
Number of subjects: 221

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 221
Study: 15166552

Group type: EXPERIMENTAL
Intervention: Predominantly low-flow cardiopulmonary bypass (LF)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Predominantly deep hypothermic circulatory arrest (CA)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Intraoperative serum glucose concentrations
Number of subjects: 171
Study: 11773285

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy offered to women whose tumors express hormone receptor protein
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Inclusion of anthracyclines in adjuvant chemotherapy regimens
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy for high-risk women after mastectomy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Postmastectomy radiotherapy for patients with one to three positive lymph nodes
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Quality of life evaluation in selected randomized clinical trials
Number of subjects: 1000
Study: 9731961

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% ointment bd for 2 weeks followed by calcipotriol 50 microg/g bd for 4 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg/g bd for 6 weeks
Number of subjects: 49
Study: 8294090

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sclerotherapy of esophageal varices (control group)
Number of subjects: 10
Study: 30342299

Group type: EXPERIMENTAL
Intervention: First-line AAD therapy
Number of subjects: 298

Group type: COMPARATOR
Intervention: First-line cryoballoon-based pulmonary vein isolation
Number of subjects: 298
Study: 27105981

Group type: EXPERIMENTAL
Intervention: Sonic powered toothbrush
Number of subjects: 64

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 64
Study: 24969718

Group type: EXPERIMENTAL
Intervention: Intermittent drainage
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Continuous drainage
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (Conventional treatment and care)
Number of subjects: 149
Study: 22643350

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Combination of Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Combination therapy (ETV + TDF)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 379
Study: 20814005

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the early group (3 to 9 months post-stroke)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the delayed group (15 to 21 months post-stroke)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups (early and delayed) received CIMT
Number of subjects: 192